Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire•12/11/2026•16:05 ET
1
Key Highlights
- ➤Q3 revenue $1.619 million, up 24% year-over-year
- ➤Q3 net income $1.8 million, or $0.29 per share
- ➤Nine-month net loss $8.9 million, versus $1.0 million loss in 2025
- ➤Zola Espresso 1-liter formulation ships this month
- ➤Zola slim cans launch in first half of 2027
- ➤Company says additional funding is required to continue operations
Expert Statements
T.J. Schaefer, CEO of Arcadia Biosciences
“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”
T.J. Schaefer, CEO of Arcadia Biosciences
“Our summer programs drove significant revenue growth and have led to new distribution opportunities in 2027 in new regions such as Texas.”
T.J. Schaefer, CEO of Arcadia Biosciences
“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”
T.J. Schaefer, CEO of Arcadia Biosciences
“In addition, we are happy to announce that our Zola Original, Original with Pulp, and Espresso varieties will be available in a 10.5-ounce slim can in the first half of next year.”
-- Zola(®) Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.(®) (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2026.
Get started
Create a free account to read the full story.